Avid Bioservices Inc (CDMO)

[dia76ca]

"IN THE DOZENS" is my favorite phrase from the last CC!

Steve King:
"In addition to the clinical trials, many of which have also have translational data points built in to tie together pre-clinical data with the clinic, we have also continued to build momentum in our pre-clinical collaborations which now number IN THE DOZENS. We are evaluating new combinations & dosing strategies combining bavituximab with chemotherapy, radiation, and immune-oncology approaches, including those targeting CTLA-4, PD-1 as well as other downstream immune checkpoints. In addition, we are evaluating combinations with other immune based approaches including vaccines and adjuvants. It is important to have a robust collaboration program so that we can identify those combinations & approaches that truly stand out and thus support advancing to the clinic. Data from these studies will also play a critical role in our ongoing discussions with potential corporate partners. We have already started to see the fruits of these collaborations with very encouraging results in preclinical models of Melanoma, Colon Cancer, and most recently Breast Cancer when combining bavituximab with other immune checkpoint inhibitors."

"Dozens" means more than one dozen....so there are at least two dozen. Could there be 3 dozen? Certainly there are 24 plus! This is very good news!